Abstract
A new anticoagulant (MD 805) was used in patients with chronic renal undergoing regular hemodialysis, and the results were compared with those of heparin. MD 805 produced no significant increase in PF-4 of the kind observed on hemodialysis with heparin. Moreover, the arterio-venous difference in β-TG during hemodialysis with MD 805 was significantly lower than that during hemodialysis with heparin. MD 805, even at the small amount of 15mg/hr, exhibited a stable antithrombin effect without marked interindividual differences in coagulation time as monitored by APTT. Consequently, it caused no increase in the proteins released as a result of platelet activation in the hemodialysis circuit.
